Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

Elliot A. Asare; Douglas B. Evans; Beth A. Erickson; Murad Aburajab; Parag Tolat; Susan Tsai

doi:10.1002/jso.24316

Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

Elliot A. Asare, Douglas B. Evans, Beth A. Erickson, Murad Aburajab, Parag Tolat, Susan Tsai

School of Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

Original language	English (US)
Pages (from-to)	291-295
Number of pages	5
Journal	Journal of Surgical Oncology
Volume	114
Issue number	3
DOIs	https://doi.org/10.1002/jso.24316
State	Published - Sep 1 2016

Keywords

cost-effectiveness
healthcare value
neoadjuvant therapy
pancreatic cancer

ASJC Scopus subject areas

Oncology
Surgery

Access to Document

10.1002/jso.24316

Cite this

@article{b2c68e7348b2415f821b1e7d1eee477f,

title = "Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer",

abstract = "Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.",

keywords = "cost-effectiveness, healthcare value, neoadjuvant therapy, pancreatic cancer",

author = "Asare, {Elliot A.} and Evans, {Douglas B.} and Erickson, {Beth A.} and Murad Aburajab and Parag Tolat and Susan Tsai",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2016",

month = sep,

day = "1",

doi = "10.1002/jso.24316",

language = "English (US)",

volume = "114",

pages = "291--295",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

AU - Asare, Elliot A.

AU - Evans, Douglas B.

AU - Erickson, Beth A.

AU - Aburajab, Murad

AU - Tolat, Parag

AU - Tsai, Susan

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

AB - Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

KW - cost-effectiveness

KW - healthcare value

KW - neoadjuvant therapy

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84983364793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983364793&partnerID=8YFLogxK

U2 - 10.1002/jso.24316

DO - 10.1002/jso.24316

M3 - Review article

C2 - 27264017

AN - SCOPUS:84983364793

SN - 0022-4790

VL - 114

SP - 291

EP - 295

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 3

ER -

Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this